all the information, none of the junk | biotech • healthcare • life sciences

The Seattle Biotech Survival Index: Companies Bounce Back in Mid-2009

(Page 2 of 3)

Dendreon (NASDAQ: DNDN)
Cash on hand: $287.5 million
Related Xconomy coverage
Dendreon Saga Heads Toward Climax, As Cancer Drug Aims to Prove It Prolongs Lives
No Devil in Details: Dendreon Data Stands Up to Scrutiny from Doctors, Investors
Dendreon Goes on Hiring Binge After Prostate Cancer Drug Boosts Survival
Dendreon Drug Works, But Can It Manufacture Enough to Meet Demand?
Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy-and-Hold Stock
Dendreon May Not Survive Its Success: Q&A with Founder Chris Henney, Part 1

Cash on hand: $9.4 million
Related Xconomy coverage:
MDRNA Cuts Executive Pay, Freezes Salaries as Cash Runs Out
MDRNA Pays Off $5.5M Debt
MDRNA Nabs $7.25M From Novartis

Cash on hand: $10.4 million
Related Xconomy coverage:
Omeros Plans to Test Waters with First Washington IPO in Two Years, Sources Say
Omeros Moves Closer To IPO, Sets Price Goal

OncoGenex Pharmaceuticals (NASDAQ: OGXI)
Cash on hand: $5.7 million
Related Xconomy coverage:
OncoGenex, Toiling in Dendreon’s Shadow, Scopes Out Partners For Prostate Cancer Drug
OncoGenex Raises $9.5M
OncoGenex Drug Helps Prostate Cancer Patients Live Longer in Small Study
Prostate Cancer Drug Vaults OncoGenex Onto Investor Radar Screens

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

Oncothyreon (NASDAQ: ONTY)
Cash on hand: $22.7 million
Related Xconomy coverage:
Goodbye Cancer Vaccines, Hello Cancer Drugs: Oncothyreon Reinvents Itself
Oncothyreon Sells Off Stimuvax, Cuts Jobs, Facilities To Preserve Cash
Oncothyreon Raises $15M

Seattle Genetics (NASDAQ: SGEN)
Cash on hand: $189.9 million
Related Xconomy coverage:
Seattle Genetics, Bucking the Trend, Recruits Hodgkin’s Patients at Warp Speed
Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting
Seattle Genetics Defies Gravity With Biotech’s First Underwritten Stock Sale in Six Months
Seattle Genetics Gets $136M Total
… Next Page »

Single Page Currently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.